Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Cash Flows (Unaudited)

v3.10.0.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
9 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities    
Net loss $ (6,500,528) $ (11,763,542)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation and amortization 46,222 31,932
Stock-based compensation 1,693,899 2,508,909
Imputed interest on loans due to former owners 1,466 2,933
Change in fair value of warrant liabilities 4,287,737
Unrealized gain on marketable securities 13,142
Changes in:    
Other current assets and prepaid expenses (26,460) 67,738
Accounts payable (7,770) 121,504
Accrued expenses (968,286) (163,857)
Net cash used in operating activities (5,748,315) (4,906,646)
Cash flows from investing activities    
Licensing right to use technology (200,000)
Investment in marketable securities (603,857)
Proceeds from redemption of marketable securities 5,730,782
Purchase of property and equipment (52,259) (219,255)
Net cash provided by (used in) investing activities 5,478,523 (823,112)
Cash flows from financing activities    
Issuance of common stock, net of offering cost 27,170
Payment of loan and interest to former owners (176,805)
Payment of line of credit (28,000)
Exercise of options 1,005
Net cash provided by (used in) financing activities 27,170 (203,800)
Decrease in cash, cash equivalents and restricted cash (242,622) (5,933,558)
Cash, cash equivalents and restricted cash at beginning of period 738,234 7,140,904
Cash, cash equivalents and restricted cash at end of period 495,612 1,207,346
Supplemental disclosure of non-cash investing activities:    
Fair market value of options to be issued to NitricGen for the licensing right to use technology $ 295,000